nevirapine nvp sold brand name viramune among others medication used treat prevent hivaids specifically generally recommended use antiretroviral may used prevent mother child spread birth recommended following taken common side effects include rash headache nausea feeling tired liver liver problems skin rash may severe checked first months appears safe use nonnucleoside reverse transcriptase inhibitor nnrti works blocking function reverse nevirapine approved medical use united states world health organizations list essential available generic nevirapine used people six years age older infected part combination antiretroviral treatment art cart monotherapy nevirapine indicated due rapid emergence nevirapine triple combination therapy shown suppress viral load effectively used initial antiretroviral therapy ie antiretroviralnaive clinical trials demonstrated comparable hiv suppression nevirapinebased regimens achieved regimens based protease inhibitor drug generally considered use cell count although concerns raised nevirapinebased regimens starting therapy high viral load low count analyses suggest nevirapine may effective group nevirapine may also form useful component salvage regimens virological failure usually combination one pis well nucleotide reverse transcriptase inhibitor nrtis especially previously taken nnrti dosing children based body surface area however weightbased dosing algorithms released guidelines include dosing algorithms young newborn although single dose nevirapine given mother child reduced rate hiv transmission almost compared short course zidovudine azt prophylaxis clinical trial trial found associated press investigation riddled sloppy recordkeeping possibly subsequent study thailand showed prophylaxis singledose nevirapine addition zidovudine effective zidovudine trials led world health organization endorse use singledose nevirapine prophylaxis many developing world settings costeffective way reducing mothertochild transmission however united states ugandan study deemed flawed fda approved nevirapine however supporters hivnet experiment argued flaws experiment largely due bureaucratic incompetence findings regarding safety efficacy singledose nevirapine study scientifically solid important moreover argued holding african researchers operated resourcepoor situations moral procedural standards western counterparts unrealistic would marginalize african researchers role science community impede progress african another clinical trial using nevirapine prevent mothertochild hiv transmission breastfeeding completed september major concern approach nnrti resistance mutations commonly observed mothers infants singledose may compromise response future nnrticontaining short course maternal lamivudinezidovudine recommended us public health service task force reduce nevirapine contraindicated nonoccupational postexposureprophylaxis including pregnant nonpregnant women due severe liver common adverse effect nevirapine development mild moderate rash severe lifethreatening skin reactions observed patients including syndrome toxic epidermal necrolysis nevirapine may cause severe lifethreatening liver toxicity usually emerging first six weeks us food drug administration issued black box warning nevirapine warning could cause lifethreatening liver toxicity skin unacceptably high risk serious liver symptoms certain patient groups women count men led us dhhs recommend restriction nevirapine use lower risk unless benefit patient clearly outweighs although study found limits effect seen patients recruited thailand recent studies use nevirapine people higher cell counts come following conclusion treatmentexperienced patients start nvpbased combination therapy low high current cell counts undetectable vl similar likelihood discontinuing nvp therapy hypersensitivity reactions hsrs compared treatmentnaive patients low cell counts suggests nvpbased combination therapy may safely initiated patients however similar patients detectable vl prudent continue adhere current cell count us public health service task force advocates caution use nevirapine pregnancy due toxicity issues may exacerbated cases immune reconstitution syndrome fat redistribution also observed us food drug administration recommends stopping nevirapine person additionally us fda recommends close monitoring first weeks therapy symptoms high risk time continued monitoring recommended first weeks treatment patient experiences hepatitis plus rash systemic symptoms severe hypersensitivity skin rash nevirapine nevirapine substrate liver enzymes concomitant administration drugs inhibitors enzymes may increase serum nevirapine levels significantly examples drugs include ritonavir fosamprenavir fluconazole hand drugs inducers enzymes rifampicin may lower serum nevirapine addition concomitant use st johns wort hypericum perforatum shown induce st johns wort containing products may significantly lower nevirapine nevirapine inducer cytochrome isoenzymes may reduce levels several coadministered drugs including antiretrovirals efavirenz indinavir lopinavir nelfinavir saquinavir well clarithromycin ketoconazole forms hormonal contraception nevirapine falls nonnucleoside reverse transcriptase inhibitor nnrti class nucleoside nonnucleoside rtis inhibit target reverse transcriptase enzyme essential viral enzyme transcribes viral rna dna unlike nucleoside rtis bind polymerase active site nnrtis bind hydrophobic pocket subdomain angstrom away active site known nnrti pocket therefore nnrtibinding pocket inhibit reverse transcription way distinct nevirapine effective pocket reverse transcriptase different structure confers intrinsic resistance nnrti resistance nevirapine develops rapidly viral replication completely common mutations observed nevirapine treatment also observed nnrtis bind within pocket viral strains resistant nevirapine usually also resistant nnrtis efavirenz delavirdine however second generation nnrtis like rilpivirine etravirine effective treatment hiv strains resistant nevirapine first generation drugs class nevirapine discovered karl hargrave colleagues boehringer ingelheim pharmaceuticals inc one boehringer ingelheim group companies covered us patent archived wayback machine corresponding foreign patents nevirapine first nnrti approved us food drug administration fda approved june adults september children also approved europe former us president george w bushs pepfar funding million help combat african aids epidemic included nevirapine among medications programs south africa treatment action campaign successfully sued government failure make nevirapine widely available minister health v treatment action campaign constitutional court south africa ordered government immediately remove restrictions prevent nevirapine made available purpose reducing risk mothertochild transmission hiv public hospitals clinics research training sites permit facilitate use nevirapine purpose reducing risk mothertochild transmission hiv make available purpose hospitals clinics judgement attending medical practitioner acting consultation medical superintendent facility concerned medically indicated shall necessary include mother concerned appropriately tested httpsenwikipediaorgwikinevirapine